652O Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC)

Kathryn C. Arbour, Salman R. Punekar, Ignacio Garrido‐Laguna, David S. Hong, Brian M. Wolpin, Meredith S. Pelster, M. Barve, Alexander Starodub, D. Sommerhalder, Sam S. Chang, Y. Zhang, Zeena Salman, X. Wang, Corinne E. Gustafson, Alexander I. Spira